Optimal Allocation of Gold Standard Testing under Constrained
  Availability: Application to Assessment of HIV Treatment Failure by Liu, Tao et al.
ar
X
iv
:2
01
0.
00
69
2v
1 
 [s
tat
.M
E]
  1
 O
ct 
20
20
Optimal Allocation of Gold Standard Testing under Constrained
Availability: Application to Assessment of HIV Treatment Failure
Tao Liu1, Joseph W Hogan1, Lisa Wang1, Shangxuang Zhang1, Rami Kantor2
1Brown University School of Public Health
2Alpert Medical School of Brown University
Abstract
The World Health Organization (WHO) guidelines for monitoring the effective-
ness of HIV treatment in resource-limited settings (RLS) are mostly based on clinical
and immunological markers (e.g., CD4 cell counts). Recent research indicates that the
guidelines are inadequate and can result in high error rates. Viral load (VL) is consid-
ered the “gold standard”, yet its widespread use is limited by cost and infrastructure.
In this paper, we propose a diagnostic algorithm that uses information from routinely-
collected clinical and immunological markers to guide a selective use of VL testing for
diagnosing HIV treatment failure, under the assumption that VL testing is available
only at a certain portion of patient visits. Our algorithm identifies the patient subpop-
ulation, such that the use of limited VL testing on them minimizes a pre-defined risk
(e.g., misdiagnosis error rate). Diagnostic properties of our proposal algorithm are as-
sessed by simulations. For illustration, data from the Miriam Hospital Immunology
Clinic (RI, USA) are analyzed.
KEY WORDS: Antiretroviral failure, constrained optimization, HIV/AIDS, resource lim-
ited, ROC, tripartite classification.
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1. INTRODUCTION
According to a recent report of the World Health Organization (WHO) (WHO 2010a), al-
most 40 million people world-wide are infected with human immunodeficiency virus (HIV).
Among them, over 97% live in resource-limited settings (RLS), particularly in sub-Saharan
Africa (UNAIDS 2010). Although the number of people living with HIV remains high, the
mortality rate due to acquired immune deficiency syndrome (AIDS) has started to decline
since 2006 (UNAIDS 2009), due in large part to the successful rollout of HIV antiretroviral
treatment (ART) in RLS (WHO 2010b).
With more and more people having access to ART, treatment failure is inevitable and
must be anticipated. Treatment failure occurs when antiretroviral medications fail to con-
trol HIV replication in infected patients. Common causes of treatment failure include
lack of proper medication adherence and development of drug resistance. The former
may be addressed by reinforcing adherence (Gardner et al. 2009), while the latter usually
mandates a switch to a more effective “next line” ART regimen (e.g., from a first- to a
second-line regimen).
Monitoring the effectiveness of HIV treatment and correctly diagnosing treatment fail-
ure in a timely manner is critical for preventing HIV-related morbidity and mortality and
transmission of the virus. Incorrect diagnosis of treatment failure can lead to undesired
consequences and compromise the success that has been achieved by rolling out ART in
RLS. Specifically, failure to diagnose treatment failure can result in continued viral repli-
cation, deterioration of patient’s immune system, extra clinical costs such as treatment of
opportunistic infections, increased risk of HIV transmission, selection of resistant strains,
and death (Anderson and Bartlett 2006; Calmy et al. 2007; Vekemans et al. 2007). Mean-
while, incorrectly diagnosing patients as having treatment failure when in fact they do not
can prompt a premature switch to the next-line ART. This generates unnecessary financial
burden (second-line therapies cost up to ten times more than first-lines) and potentially
accelerates progression toward resistance to next-line therapies, which are most probably
the last line in RLS (Vekemans et al. 2007).
In resource-rich countries such as those in much of western Europe and North Amer-
ica, viral load (VL) testing is routine for HIV treatment monitoring (Thompson et al. 2010;
DHHS 2011). In this paper, VL refers to the amount of HIV in the blood as measured us-
ing nucleic acid amplification (Hammer et al. 2006). It is a marker that directly reflects the
effectiveness of HIV treatment. Although HIV cannot be eradicated now, patients with
adequate adherence can be expected to have viral suppression, which generally means that
VL is below the lower detection limit of the assay being used (assays used for clinical
purposes have lower detection limits of between 20 and 1000 copies/mL). A patient on
adequate ART who has detectable VL after having previously reached an undetectable
level is said to have virological treatment failure (hereafter “viral failure” or “treatment fail-
ure”), an indication that the particular treatment regimen may no longer be effective.
In RLS, VL testing is either limited or not available due to factors such as cost, lack
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of facilities, and lack of properly trained personnel (Fiscus et al. 2006; Calmy et al. 2007;
Schooley 2007). Therefore, diagnosis of HIV treatment failure is commonly made using
lower-cost and less accurate markers such as current CD4 cell count, CD4 percent among
all lymphocytes, and relative changes in thesemeasures since last visit; and clinical indica-
tors such as opportunistic infections, weight loss, and HIV-related malignancies. Indeed,
these immunological and clinical markers form the basis of HIV treatment monitoring
guidelines as recommended by the WHO (Calmy et al. 2007; WHO 2010a). These guide-
lines are widely adopted by countries in sub-Saharan Africa (e.g., Malawi 2003; Uganda
2003; Zambia 2004; Kenya 2005) and other developing regions.
Although CD4-based markers are generally associated with VL, a consensus has been
reached recently that their use for diagnosing HIV treatment failure is prone to high mis-
classification rates (Deeks et al. 2000, 2002;Moore et al. 2005; Bisson et al. 2006; Schechter and Tuboi
2006; Tuboi et al. 2007; Bisson et al. 2008;Mee et al. 2008; Castelnuovo et al. 2009; Kantor et al.
2009; Keiser et al. 2009; Meya et al. 2009; Reynolds et al. 2009; Kiragga et al. 2012). Data
from a recent study of patients receiving care through the Academic Model Providing Ac-
cess to Healthcare (AMPATH) in western Kenya show that almost 40% of those having
treatment failures would have been incorrectly diagnosed based on the WHO guidelines
(Kantor et al. 2009).
Several studies have investigated monitoring HIV treatment using markers in addi-
tion to or instead of CD4 cell count (Bagchi et al. 2007; Kantor et al. 2009; Foulkes et al.
2010; Abouyannis et al. 2011). Bagchi et al. (2007) showed that weight loss is associated
with treatment failure but pointed out that its clinical utility is limited because weight is
influenced by many factors. Kantor et al. (2009) found in a Kenyan cohort that time on
therapy and change in CD4 percent can be potentially incorporated into CD4-based rules
to improve the diagnosis of treatment failure. Abouyannis et al. (2011) developed and
tested a scoring system that incorporates CD4 count, mean cell volume, medication adher-
ence, and HIV-associated clinical events for diagnosing treatment failure. Foulkes et al.
(2010) proposed a prediction-based classification method that combines multiple time-
varying clinical measures for predicting treatment failure. Each of these studies focuses
on augmenting or replacing CD4 count with other immunological and clinical markers,
assuming that VL testing is completely unavailable. Potential improvements are demon-
strated, but often found to be marginal.
In this paper, we consider augmenting rules of diagnosing treatment failure based on
low-cost markers (such as CD4 cell count) with a selective use of VL testing, under the
assumption that VL testing can be ordered only for a fixed portion of patient visits. Our
approach is motivated by the fact that several HIV care programs in developing countries
have started to conduct VL testing for some of their patients. For example, as a result of
the study by Kantor et al. (2009), AMPATH is currently conducting VL testing at about ten
percent of its patient visits when treatment failure is suspected. Our approach is also mo-
tivated by the expectation that as technology and training advance (e.g., Greengrass et al.
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2009), VL testing will be more affordable, even if substantially limited in the near future.
Assuming that VL testing is available but at a fixed portion of patient visits, we pro-
pose a tripartite classification procedure to triage VL testing based on a risk score S de-
rived from low-cost non-VL markers. Specifically, the resulting tripartite diagnostic rule
comprises two cut-off values l and u on S, with l ≤ u, that classify HIV patients into three
mutually exclusive categories (refer to Figure 1), and correspondingly takes one of the
following three actions for each category.
(a): Those with S > u are diagnosed as failing treatment,
(b): Those with S ≤ l are diagnosed as non-failing, and
(c): Those with l < S ≤ u are designated for VL testing, which will provide an error-free
diagnosis.
The tripartite diagnostic rule is designed to minimize a pre-specified risk (e.g., mis-
classification) subject to the constraint on the availability of VL assays. To identify the op-
timal rule, we develop both nonparametric and semiparametric approaches to inference
about l and u. We also develop a receiver operating characteristic (ROC) analysis proce-
dure for a general assessment of candidate tripartite rules. The ROC curve and the area
under the ROC curve (AUC) provide a comprehensive measure of diagnosis capacity of
tripartite rules, and allow us to evaluate the potential improvement that can be achieved
by increasing VL testing availability. ROC analysis of tripartite rules has many statistical
properties that are similar to conventional ROC analysis of bipartite rules.
The rest of the paper is organized as follows: Notations, definitions, and criteria for
rule development are given in Section 2; nonparametric and semiparametric approaches
to optimal rule selection are presented in Section 3; ROC analysis of tripartite rules is
described in Section 4; and simulation studies are conducted in Section 5. For illustration,
data from the HIV Immunology Clinic of the Miriam Hospital (RI, USA) are analyzed in
Section 6. We conclude with a summary and discussion of future research in Section 7.
2. NOTATIONS AND DEFINITIONS
2.1 HIV Viral Status and Risk Score
The objective of HIV treatment monitoring is to diagnose viral failure. Let V denote a
patient’s (possibly unmeasured) viral load. Viral failure is said to occur when V exceeds a
pre-specified threshold v∗, where v∗ is typically the lower detection limit of the VL assay
being used. Let Z = 1(V > v∗) denote viral status with Z = 1 indicating a viral failure
and 0 otherwise, where 1(·) is the indicator function. The prevalence of viral failure is
denoted by p = Pr(Z = 1). At each patient encounter, a set of immunological, clinical,
and demographic markers is usually collected, which may include CD4 count, CD4 per-
cent among all lymphocytes (and recent changes in both), WHO stage, time on therapy,
4
Figure 1: Risk score distributions and diagnosis actions.
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hemoglobin, weight, age, gender, and adherence measures. Henceforth, these markers
are generically referred to as low-cost clinical markers and denoted by a vector X.
For each individual, these clinical markers are translated into a scalar risk score S =
S(X). Several recent studies have proposed versions of S(X) for determining the risk
of treatment failure (e.g., Lynen et al. 2009; Meya et al. 2009; Abouyannis et al. 2011). If
S(X) is a predicted probability of viral failure given X, it can be derived using logis-
tic regression, regression trees, or other types of prediction-based classification methods
(e.g., Pepe and Thompson 2000; Hastie et al. 2001; Foulkes et al. 2010; Justice et al. 2010;
van der Laan 2011). In this paper, we assume that the functional form of S(·) is known,
but note that finding and validating an optimal form of S(X) is an important topic of
research (see Huang et al. 2007; Pepe et al. 2008; Steyerberg et al. 2010; Pepe 2011)
Let G1 and G0 denote the distributions of S for patients with viral failure (Z = 1) and
viral suppression (Z = 0), and g1 and g0 denote their associated densities, respectively.
The population distribution of S is therefore a mixture distribution G = (1− p)G0 + pG1,
whose density is denoted by g. We assume that for independent observations S and S′,
where S ∼ G1 and S′ ∼ G0, S is stochastically greater than S′ in the sense that on average,
patients with viral failure have higher risk scores. An illustration of g0, g1, and g leading
to a hypothetical distribution of S is presented in Figure 1.
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2.2 Classification Cut-offs and Tripartite Rules
The tripartite diagnostic rule can be formalized as follows. Let l and u, with l ≤ u, sub-
divide the population into three categories: those whose risk of treatment failure is high
(S > u), low (S ≤ l), or intermediate (S ∈ I ≡ (l, u]). Let δI (S) denote the diagnostic de-
cision based on S, with δI (S) = 1 indicating a treatment failure diagnosis and δI (S) = 0
a non-failing diagnosis. Then our tripartite rule is expressed as
δI (S) =

0 if S ≤ l,
Z if S ∈ I ,
1 if S > u.
(1)
This rule obtains the gold standard measurement for the intermediate risk subpopulation
{S ∈ I }, which carries the greatest uncertainty about true viral status. Note that when
S ∈ I , the diagnosis decision corresponds to the true viral failure status and therefore
leads to a correct diagnosis.
2.3 Loss and Risk Functions
Let L(d, z) denote the loss or cost incurred when the true viral failure status is Z = z and
a diagnostic decision d is taken. Two commonly used loss functions in studies of medical
diagnosis are L1(d, z) = 1(d 6= z), which indicates whether a misdiagnosis occurs, and
L2(d, z) = {1(d = 0, z = 1), 1(d = 1, z = 0)}⊤, which indexes misdiagnoses separately
for those with viral failure (i.e., false negative, FN) and those without (i.e., false positive,
FP). Loss functions can be made more elaborate and extended to incorporate potential
costs as well as benefits of correct and incorrect diagnoses (e.g., expected mortality, cost
of switching to next-line therapies, and gain of life expectancy); see Parmigiani (2002) for
further discussions.
The development of our diagnostic rule also uses a weighted loss function
L3(d, z;λ) = λ1(d = 0, z = 1) + (1− λ)1(d = 1, z = 0),
where λ ∈ [0, 1] is a user-specified weight that reflects relative loss for the two types of
misdiagnoses. At the extremes, setting λ = 1 places the highest priority on avoiding FN
(incorrectly diagnosing a patient as non-failing), while λ = 0 prioritizes avoidance of FP
(incorrectly diagnosing a patient as treatment failure). An appropriate and meaningful
value of λ should be contextually specific and take into account the available information
about patient’s health status and various costs associated with FP and FN.
The overall diagnostic accuracy of a diagnostic rule is summarized by a risk function
defined as R(I ) = E[L(δI (S),Z)], where the expectation is taken over the joint distribu-
tion of (S,Z)⊤ (Berger 1985). For the loss function L1, R1(I ) = E[1{δI (S) 6= Z}] is the
total misclassification rate (TMR). For L2, R2(I ) = {pFNR, (1− p)FPR}⊤, where FNR
and FPR are the FN and FP rates, respectively. For L3, we have a weighted sum of FPR
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and FNR
R3(I ;λ) = λpFNR+ (1− λ)(1− p)FPR, (2)
where the weights depend on both λ and the prevalence of viral failure. Risk function
R3(I ;λ) is one form of ‘net benefit’ functions that have been used in decision curve anal-
yses and utility analyses (Vickers and Elkin 2006; Baker 2009). As a special case when
λ = .5, minimizing R3(I ; .5) is equivalent to minimizing R1(I ).
In the next section, we develop methods for obtaining optimal rules under the risk
criteria R1(I ) and R3(I ;λ). The optimal rules that minimize R1(I ) and R3(I ;λ) are
called the min-TMR rules and min-λ rules, respectively. In Section 4, the vector-valued
risk function R2(I ) is used to develop a ROC analysis procedure for a general assessment
of tripartite diagnostic rules.
3. OPTIMAL RULE SELECTION: CONSTRAINED OPTIMIZATION
3.1 Characterization of Constraints on Gold Standard Testing
Suppose that VL tests can be ordered for a fixed portion φ of patient visits, where 0 ≤ φ ≤
1. Then the proposed tripartite rules must satisfy the constraint
G(u)− G(l) ≤ φ. (3)
In the extreme cases, φ = 0 means that no VL testing is available, while φ = 1 means that
it is available at all patient visits.
Tripartite diagnostic rules that satisfy (3) can be infinitely many, because if δI (s) sat-
isfies (3), so does δI ′(s) for all I
′ ⊂ I . We therefore restrict attention only to those rules
that take maximum advantage of the available VL tests. All such rules form our decision
space. Specifically, the decision space is defined as the set DGφ = {δI : G(u)− G(l) ≤ φ}
with the condition that for any δI (s) ∈ DGφ , there does not exist another rule δI ′(s) with
I ′ ⊃ I and satisfying (3).
For a given risk function R(·) and a decision space DGφ , the optimal rule is defined as
δI ∗ = argmin
δI∈DGφ
{R(I )}, (4)
where I ∗ indicates the optimal cut-offs on S for triaging the VL tests. We assume that the
optimal rule is unique.
3.2 Optimal Rule Selection
In this section, we develop nonparametric and semiparametric approaches to determin-
ing the optimal rule from DGφ . The nonparametric approach places no distributional as-
sumption on either G0 or G1 and can therefore be broadly applied. The semiparametric
approach assumes that G0 and G1 follow an exponential tilt model, whereby the densities
g0(s) and g1(s) differ only by a factor proportional to exp(β1s), where β1 is an unknown
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scalar parameter (called the tilting parameter). In Section 5, we use simulations to show
that when the exponential tilt assumption holds, the semiparametric approach is gener-
ally more efficient in estimating the optimal rule when sample size is large.
Nonparametric Approach.
Suppose that we have a training data set of independent pairs (S1,Z1), . . . , (Sn,Zn). We
first estimate G1, G0, and G empirically via
Ĝz(s) =
∑
n
i=1 1(Si ≤ s,Zi = z)
∑
n
i 1(Zi = z)
, z = 0, 1,
Ĝ(s) = p̂Ĝ1(s) + (1− p̂)Ĝ0(s)
with p̂ = ∑ni=1 Zi/n. To determine the optimal rule using (4), we then obtain the empirical
decision space D Ĝφ by the following steps:
1. Write L˜ = (l˜1, l˜2, . . . , l˜n)
⊤ = (S(1), S(2), . . . , S(n))⊤, where l˜j = S(j) is the j-th order
statistic of S = (S1, . . . , Sn)
⊤.
2. For each l˜j, calculate u˜j = argmaxu∈S{Ĝ(u)− Ĝ(l˜j) ≤ φ}. Let U˜ = (u˜1, u˜2, . . . , u˜n)⊤.
3. For u˜j and u˜j′ ∈ U˜, j < j′, if u˜j = u˜j′ , drop l˜j′ from L˜ and u˜j′ from U˜. Denote the
resulting vectors by L̂ = (l̂1, l̂2, . . . , l̂m)
⊤ and Û = (û1, û2, . . . , ûm)⊤ with m ≤ n.
4. The empirical decision space is given by D Ĝφ = {δÎj : j = 1, 2, . . . ,m} with Îj =
(l̂j, ûj].
With the empirical decision space D Ĝφ , the optimal rule is then estimated via (4) with
DGφ replaced by D
Ĝ
φ . This can be carried out using a grid search. For example, to estimate
the optimal rule that minimizes TMR, we calculate F̂NRj = Ĝ1(l̂j) and F̂PRj = 1− Ĝ0(ûj)
for j = 1, . . . ,m. Then, the optimal min-TMR rule is the rule in D Ĝφ that has a risk equal
to min
j
( p̂FNRj + (1− p̂)F̂PRj). Similarly, to identify the rule that minimizes R3(I ;λ) for
a pre-specified λ, we select the rule in D Ĝφ that has a risk of min
j
(λ p̂FNRj + (1− λ)(1−
p̂)F̂PRj).
Semiparametric Approach
The exponential tilt model has been used to characterize the relationship between compo-
nents of a mixture distribution (Anderson 1972, 1979; Prentice and Pyke 1979; Efron 1981;
Qin 1999). The model places no parametric assumptions on individual components of the
mixture, except assuming that they differ only by a factor of the form
g1(s) = exp(β
∗
0 + β1s)g0(s), (5)
8
where β1 is an unknown tilting parameter and β
∗
0 = − log EG0(eβ1S) is a normalizing
constant. Although no constraints are placed on g0, many commonly-used parametric
distribution families can be represented in the form of (5), such as binomial, Poisson, nor-
mal with a common variance, and gamma distributions with a common shape parameter.
In our case, the exponential tilt model is equivalent to the logistic model
logit{Pr(Z = 1 | S = s)} = β0 + β1s (6)
with logit(y) = log{y/(1− y)} and β0 = β∗0 + logit(p).
When the exponential tilt assumption holds, we can estimate G0 and G1 semipara-
metrically using the results in Appendix A.1, and then estimate the optimal rule using a
grid-search in a similar way to what has been described in the last section.
If our goal is to identify a rule that minimizes TMR, it turns out that we can readily
determine this rule without calculating the semiparametric estimates of G0 and G1. To see
this, wewrite Γ(l, u, τ) = R1(I )+ τ(G(u)−G(l)−φ), and apply the Lagrangemultiplier
to solve ∂Γ/∂(l, u, τ)⊤ = 0. It is straightforward to verify that the resulting rule must
satisfy
l+ u = −2β0
β1
, G(u)− G(l) ≈ φ.
That is, the optimal interval I ∗ for triaging the limited VL testing is centered at −β0/β1,
independent of the VL test availability φ. The optimal cut-off values therefore can be
estimated by l̂ = −β̂0/β̂1 − ∆φ and û = −β̂0/β̂1 + ∆φ, where β̂0 and β̂1 are parameter
estimates of the logistic model (6) and
∆φ = argmax
s
{Ĝ(−β̂0/β̂1 + s)− Ĝ(−β̂0/β̂1 − s) ≤ φ}.
In the above equation, the empirical estimate Ĝ is used because the semiparametric esti-
mate of G under the exponential tilt model is the same as Ĝ.
Uniqueness of Estimated Optimal Rule.
The estimated optimal rule based on a finite data set may not be unique, even though
the true optimal rule is unique. When there are multiple rules that meet the optimality
criterion, we propose to impose additional secondary criteria so as to determine a single
optimal rule. For example, to determine an optimal rule from multiple rules that equally
minimize R3(I ;λ), we may consider adding R1(I ) as a secondary criterion and choos-
ing one from these rules that has the lowest TMR. It is also reasonable to randomly choose
one for practical use if the estimated optimal rules differ little.
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4. ROC ANALYSIS
ROC analyses have been widely used to assess the overall diagnostic accuracy of bipar-
tite classification rules. An ROC curve is a graphical presentation of the risk function
R2(·) associated with all candidate rules in a decision space. Comprehensive reviews of
ROC analyses in biomedical research can be found in Pepe (2000), Zhou et al. (2002, Ch
2), Pepe (2003, Chs 4-5), and Gatsonis (2009). Recent applications of ROC analyses in
studies of HIV-infected populations include Pahwa et al. (2008), Joska et al. (2011), and
Mabeya et al. (2012), among many others.
4.1 ROC Curve for Tripartite Rules and AUC
ROC analyses for tripartite rules can be carried out in a fashion similar to conventional
ROC analyses. With each rule in DGφ represented by a point in a 2-dimensional space with
its (FPR, 1−FNR) as the coordinates, an ROC curve for tripartite rules can be generated
by connecting these points using a non-decreasing curve. Mathematically, we can express
the ROC curve for tripartite rules as
Cφ(t) : t ∈ [0, 1] 7→ 1− G1 ◦ Hφ ◦ G−10 (1− t), (7)
where G−10 (t) = inf{s : G0(s) ≥ t} is the generalized inverse of a cadlag function,
Hφ(u) = arg infw{G(u) − G(w) ≤ φ}, and ‘◦’ denotes the function composition opera-
tor. Note that the difference between (7) and a conventional ROC curve is the operation
induced by Hφ, which dictates that for each u and resulting FPR, the corresponding FNR
is calculated based on a lower cut-off l = Hφ(u) ≤ u.
The area under the ROC curve (AUC) for tripartite rules is defined as,
AUCφ =
ˆ 1
0
Cφ(t)dt. (8)
Like AUC for bipartite classification rules, AUCφ provides an omnibus measure of diag-
nostic capability of all candidate rules in DGφ . It can be interpreted as the true positive
rate averaged across all FNRs. In Appendix A.2, we present several properties of AUCφ,
which turn out to be very similar to the AUC from a conventional ROC analysis.
As a special case when φ = 0, Cφ(t) and AUCφ reduce to conventional ROC curve and
AUC for bipartite rules.
4.2 Estimation
With a training data set of independent (S1,Z1), . . . , (Sn,Zn) and a given φ, we can esti-
mate the ROC curve for tripartite rules nonparametrically by
Ĉφ(t) = 1− Ĝ1 ◦ Ĥφ ◦ Ĝ−10 (1− t), (9)
10
where Ĝ0 and Ĝ1 are empirical estimates, and Ĥφ(u) = argminw{Ĝ(u)− Ĝ(w) ≤ φ}. The
estimated ROC curve is a step function with jumps only at points representing the rules
in D Ĝφ . When the exponential tilt assumption holds, the ROC curve also can be estimated
semiparametrically by replacing Ĝ0 and Ĝ1 in (9) by their corresponding semiparametric
estimates given in Appendix A.1.
Using the results in the Appendix A.2 (See Eq.(A.1)), we can estimate AUCφ nonpara-
metrically by
ÂUCφ =
1
n2 p̂(1− p̂)
n
∑
j=1
n
∑
i=1
Zi(1− Zj)
[
1{Si > Ĥφ(Sj)}+
1{Si = Ĥφ(Sj)}
2
]
. (10)
In Appendix A.3, we present several large-sample properties of the nonparametric esti-
mates Ĉφ(t) and ÂUCφ.
4.3 Using ROC curve for Rule Selection
An ROC curve for tripartite rules also can be used for optimal rule selection, recognizing
that the diagnostic properties of each rule in DGφ are characterized by a point on the curve.
For example, if the ROC curve is smooth and concave, it can be verified that the min-λ
rule corresponds to the point on the ROC curve where the tangent is equal to (1− λ)(1−
p)/(λp) (Metz 1978). Broader discussions on using ROC curves for optimal rule selection
can be found in Zhou et al. (2002) and Pepe (2003).
5. SIMULATION STUDIES
In this section, we conduct simulation studies to examine 1) the diagnostic accuracy of the
optimal rules estimated by the nonparametric and semiparametric approaches, and 2) the
large-sample properties of the estimated optimal rules. For the first aim, we consider two
scenarios when the exponential tilt assumption is and is not satisfied. For the second aim,
we focus on the setting where the exponential tilt assumption holds. For simplicity, we
consider estimating the optimal rules that minimize TMR.
We use the negative value of CD4 count as a risk score. We first simulate viral status
Z assuming that Z ∼ Bernoulli(p), and then conditional on Z, simulate (CD4|Z = z) =
⌈W⌉ withW ∼ Gamma(ηz, κz), where ⌈·⌉ denotes the ceiling operation, and ηz and κz are
the shape and scale parameters of the gamma distribution.
Scenario (A) considers the case when the exponential tilt assumption does not hold.
We conduct two simulations by simulating CD4 count data from gamma distributions
with parameters,
(A-1): (η0, κ0) = (3.2, 152) and (η1, κ1) = (2.3, 133)
(A-2): (η0, κ0) = (4.8, 100) and (η1, κ1) = (2.3, 133).
The parameter values of (A-1) are chosen as the maximum likelihood estimates (MLEs)
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obtained by fitting gamma distributions to the Miriam Immunology Clinic data (which
will be analyzed in Section 6). For (A-2), we choose the same values of (η1, κ1) as in (A-1),
but set (η0, κ0) such that the exponential tilt assumption is further violated while keeping
η0κ0 unchanged, i.e. the average CD4 count for patients without treatment failure stays
the same as (A-1). (Recall that the mean of gamma distribution is ηκ.)
Scenario (B) considers the case when the exponential tilt assumption holds. We choose
a common shape parameter η0 = η1 = 2.8, the mid-point of η0 and η1 in (A-1), and
conduct two simulations with parameters
(B-1): (η0, κ0) = (2.8, 173) and (η1, κ1) = (2.8, 111)
(B-2): (η0, κ0) = (2.8, 350) and (η1, κ1) = (2.8, 111).
The values of κ0 and κ1 in (B-1) are the MLEs obtained by fitting gamma distributions to
the Miriam Immunology Clinic data while fixing their shape parameters at 2.8. For (B-2),
we choose a large value of κ0 = 350 to simulate a case when two gamma distributions are
further separated. The gamma densities of the four simulations are shown in Figure 2.
5.1 Diagnostic Accuracy
For the first aim, we consider three prevalences of treatment failure, p = (.15, .25, .40),
and assume that VL testing is available at proportions φ = (0, 20, 40)% of patient visits.
For each parameter combination, we simulate 1000 datasets each having 5000 observa-
tions. The first 2500 observations of each dataset are used as the training data to develop
an optimal rule, and the remaining 2500 observations as the testing data to calculate its
associated misclassification rate. Results are shown in Table 1.
When the prevalence of treatment failure is low (e.g., p ≤ .25) and VL test availability
φ is high, the semiparametric approach may yield a negative estimate of the lower cut-off
value on CD4 count, particularly when the center of the optimal cut-off interval is close to
zero. When this occurs, we replace the negative cut-off values by zero. This adjustment
does not imply that the algorithm fails. It can be verified that the upper cut-off estimate is
still correct, and the optimal rule in this case is to assign VL test to those high-risk patients
with CD4 count less than the upper cut-off value.
Table 1 shows that the nonparametric approach yields the correct estimates of the op-
timal cut-off values for both Scenarios (A) and (B), and the resulting TMRs are close to
the underlying truth. When the exponential tilt assumption does not hold as in Scenario
(A), the optimal rules estimated by the semiparametric approach are slightly biased (con-
trasted with Scenario (B)). However when the exponential tilt assumption holds as in
Scenario (B), the semiparametric approach yields the correct estimates of the optimal cut-
off values, and the estimated cut-off values have much smaller standard errors compared
with their corresponding nonparametric estimates.
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Figure 2: Gamma distributions used for simulating CD4 count data. The gray step lines in
the top-left subplot are histograms of the CD4 data from the Miriam Hospital Immunol-
ogy Clinic. The smooth dashed (solid) lines are gamma densities for those with (without)
treatment failure.
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Table 1: Simulation results. For each condition, the estimated lower and upper cut-off
values are averages over 1000 simulations, and converted to the original scale of CD4
count. The numbers in parentheses are standard errors.
p φ
true values nonparametric estimate semiparametric estimate
lower upper TMR lower upper TMR lower upper TMR
(A-1) .15 0 65 65 .15 70 (20) 70 (20) .148 0 (1) 0 (1) .150
.2 0 230 .09 29 (14) 231 (5) .086 0 (0) 230 (5) .086
.4 0 348 .05 25 (13) 349 (6) .051 0 (0) 348 (6) .051
.25 0 125 125 .24 128 (23) 128 (23) .237 79 (25) 79 (25) .240
.2 66 225 .15 71 (21) 228 (9) .152 2 (8) 214 (5) .153
.4 39 333 .09 47 (20) 336 (7) .092 0 (0) 329 (6) .092
.4 0 239 239 .32 240 (28) 240 (28) .327 268 (13) 268 (13) .327
.2 177 288 .23 192 (22) 302 (22) .233 212 (13) 323 (14) .234
.4 149 378 .15 148 (22) 377 (22) .153 153 (14) 382 (14) .152
(A-2) .15 0 130 130 .14 132 (16) 132 (16) .135 35 (23) 35 (23) .147
.2 72 268 .07 71 (20) 268 (6) .075 0 (0) 262 (5) .075
.4 57 373 .04 59 (21) 374 (6) .045 0 (0) 370 (5) .045
.25 0 176 176 .21 178 (17) 178 (17) .209 148 (17) 148 (17) .212
.2 122 270 .13 121 (17) 269 (9) .131 51 (28) 247 (7) .135
.4 98 368 .08 96 (18) 368 (8) .080 1 (3) 351 (5) .083
.4 0 249 249 .29 251 (20) 251 (20) .291 290 (10) 290 (10) .295
.2 200 312 .20 203 (17) 314 (15) .201 236 (11) 345 (11) .204
.4 167 394 .13 169 (18) 396 (15) .130 177 (11) 403 (10) .130
(B-1) .15 0 0 0 .15 27 (15) 27 (15) .150 0 (0) 0 (0) .150
.2 0 220 .10 20 (9) 221 (5) .095 0 (0) 221 (5) .095
.4 0 338 .05 18 (8) 338 (6) .056 0 (0) 338 (6) .055
.25 0 45 45 .25 69 (34) 69 (34) .251 45 (25) 45 (25) .250
.2 0 209 .17 33 (19) 211 (6) .166 0 (2) 209 (5) .165
.4 0 322 .10 26 (14) 323 (6) .100 0 (0) 322 (6) .099
.4 0 259 259 .35 257 (34) 257 (34) .355 259 (15) 259 (15) .353
.2 215 321 .26 206 (28) 312 (29) .259 207 (15) 312 (15) .258
.4 159 379 .17 148 (31) 370 (30) .171 149 (16) 369 (15) .170
(B-2) .15 0 241 241 .13 241 (31) 241 (31) .127 242 (13) 242 (13) .126
.2 99 383 .05 103 (37) 391 (19) .047 97 (20) 386 (11) .047
.4 0 619 .01 38 (19) 622 (14) .011 0 (0) 620 (13) .010
.25 0 344 344 .16 345 (30) 345 (30) .165 345 (10) 345 (10) .164
.2 234 452 .08 237 (22) 455 (25) .082 236 (10) 454 (11) .081
.4 112 577 .03 111 (33) 581 (26) .028 111 (13) 578 (11) .028
.4 0 457 457 .18 458 (30) 458 (30) .184 458 (9) 458 (9) .183
.2 344 564 .10 347 (20) 567 (30) .100 347 (8) 568 (12) .100
.4 237 671 .05 240 (19) 677 (38) .047 239 (8) 676 (13) .046
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Figure 3: Large-sample convergence properties of estimated optimal cut-off boundaries.
Horizontal lines are added to indicate the sample sizes needed to achieve σn = 25.
0 2000 4000 6000 8000
0
10
20
30
40
50
60
Nonparametric
Sample size n
σ
n
lower cutoff
upper cutoff
∝ n−1 3
0 2000 4000 6000 8000
0
10
20
30
40
50
60
Semiparametric
Sample size n
σ
n
lower cutoff
upper cutoff
∝ n−1 2
5.2 Convergence Rate and Efficiency
The second aim of our simulation studies is to examine the relative efficiency of the non-
parametric and semiparametric approaches. For this aim, we consider only the parameter
setup of (B-2) with p = .25 and φ = .20, but simulate the training data with increasing
sample sizes of n = (250, 500, 1000, 2000, 5000, 10000). For each sample size, we simulate
1000 training datasets, and for each data set, we estimate the optimal rules both nonpara-
metrically and semiparametrically.
With a slight abuse of notation, we use σ2n to denote the variances of both estimated
upper and lower cut-off values. Then assuming that σn ∝ n
−w (a sufficient condition for
σn = O(n−w) as n → ∞), we use simulations to approximate w for the two estimation
approaches. Specifically, we compute σn based on the 1000 estimated optimal cut-off val-
ues for each sample size n. We then regress log(σn) on (− log n) using a simple linear
model with a slope w. By least-squares estimation, we find that w ≈ 0.33 when the opti-
mal cut-off values are estimated nonparametrically, and ≈ 0.50 when they are estimated
semiparametrically. The results are shown in Figure 3.
The simulations suggest that in this specific case, the nonparametric estimates of the
optimal cut-off values converge approximately at a rate of O(n−1/3), and the semipara-
metric estimates converge at a faster rate of about O(n−1/2). The relative efficiency be-
tween the two estimation approaches is approximately O(n1/6) when n is large.
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Table 2: Summary statistics for key variables (n = 597)
Marker mean median IQR range
Virological marker
VL at most recent visit (copies/mL) 11.8K 75 (75, 400) (12, > 500K)
Immunological markers
CD4 count at most recent visit (cells/uL) 442 407 (254, 576) (8, 1412)
6-month CD4 count change (%) 7.3 18 (−13, 33) (−80, 736)
CD4 % at most recent visit 24 23 (17, 30) (.90, 59)
6-month CD4% change (%) 9.5 4.7 (−6.1, 16) (−74, 209)
K: thousand; IQR: Interquartile range.
5.3 Simulation-Based Study Design
The results above also suggest that a study for tripartite rule development can be designed
based on simulations. For example, suppose that the same assumptions as in Section 5.2
are made, and we would like to design a study to determine an optimal tripartite rule
such that the 95% confidence intervals of both upper and lower cut-offs have widths of no
more than 100 CD4 (i.e., σn ≤ 25). Then referring to the gray horizontal lines in Figure 3, a
study with a sample size of about 3000 subjects is needed if the nonparametric approach
is used to estimate the optimal rule, or a sample size of about 500 if the exponential tilt
assumption holds and the semiparametric approach is used.
6. APPLICATION
6.1 Data from the Miriam Hospital Immunology Clinic
For illustration, we analyze data from the Miriam Immunology Clinic in Providence, RI,
USA, the largest HIV clinic in the state (Gillani 2009). We recognize the essential difference
between HIV-infected patients in the US and RLS. The main reason we use a US dataset
to demonstrate the development of clinical rules is because this database contains high
quality CD4 and VL data that were routinely and frequently collected.
We use data from the most recent clinic visits of 597 patients who meet the following
criteria: have taken ART for at least 6 months; have CD4 count, CD4% and VL measure
available at themost recent clinic visit; and have CD4 count and CD4% available 6 months
(with a window of 6± 1 mo) prior to that visit. We calculate the 6-month changes in CD4
count and in CD4%, where [6-month change] is defined as ([current] − [6-mo ago])/[6-
mo ago]. Total time on ART, while a potentially important predictor (Kantor et al. 2009),
is not available for all patients and therefore not used in formulating risk scores.
Table 2 provides summary statistics for key clinical and immunological markers in the
data. For uniformity, viral failure is defined as having VL above 400 copies/mL (some
of the VL test assays used have lower detection limits of < 400 copies/mL). Among the
597 patients, 146 have viral failure; so the estimated prevalence of viral failure is p̂ =
146/597 = .25.
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6.2 Risk Scores
Two risk scores are considered for developing diagnostic rules. The first risk score is S1 =
−CD4, or negative value of the most recent CD4 count (to be consistent with the notion
that greater values of S correlate with increased risk of viral failure). The second risk
score is a prediction-based composite score derived from a logistic regression of treatment
failure on four immunological markers as follows,
S2 = logit
−1(β0+ β1[CD4]+ β2[CD4 %]+ β3[6-mo CD4 change]+ β4[6-mo CD4% change]),
where CD4 and CD4% refer to their measures at current visit. The MLEs (SEs) of the
coefficients are β̂0 = .89 (.27), β̂1 = −.0021 (.00074), β̂2 = −.049 (.017), β̂3 = −.055 (.21),
and β̂4 = −1.40 (.46). A Hosmer-Lemeshow test gives a p-value of .28, indicating no
evidence of lack of fit. The distribution of S2 has a median .21, ranges from .01 to .87, and
can be interpreted as the predicted probability of treatment failure.
The risk score S1 is easier to implement in clinical practice but known to have a high
error rate for diagnosing viral failure. By incorporating more clinical information, S2 is
potentially more accurate, but its use in clinical settings is not as straightforward as S1.
6.3 Two Simple Rules
Before calculating tripartite rules based on criteria laid out in Section 3, we summarize
operating characteristics of two simple diagnostic rules that are similar in spirit to those
commonly used in RLS when VL test has limited or no availability.
The first rule assumes that no VL testing is available (i.e., φ = 0) and uses CD4< 200 as
the hard cut-off for diagnosing treatment failure and CD4 ≥ 200 as non-failing, a criterion
recommended by the WHO for the RLS (WHO 2010b). (Another criterion recommended
by the WHO for the RLS is using CD4 = 350 as the cut-off threshold.)
The second rule assumes that the limited VL testingwill be used only as a confirmative
test for patients with CD4 < 200. This rule classifies those with CD4 count ≥ 200 as non-
failure, and makes correct diagnoses for patients with CD4 count < 200. In the Miriam
Immunology Clinic data, about 15% of patients have current CD4 count less than 200, so
we consider the case that VL testing is available at 15% of patient visits, i.e., φ = .15.
The diagnostic accuracies of these two rules are summarized in Table 3. Both rules
have FNR around 0.70. The second rule, by having 15% of patients tested for VL, reduces
the FPR to 0 and TMR from .26 to .18. The improvement realized by having VL testing
available to a small fraction of patients is evident; however, whether the second rule is
optimal needs further investigations.
6.4 Analysis I: CD4-Based Min-λ Rules
In this section, we evaluate the diagnostic performance of optimal tripartite rules based
on S1, using R3(·) as the risk criterion. To make a direct comparison to the simple rules
17
Table 3: Diagnostic accuracies of the two simple empirical rules.
Diagnosis action based on CD4
φ test positive request VL test test negative FPR FNR TMR
0 0 - 200 – ≥ 200 .10 .70 .26
.15 – 0 - 200 ≥ 200 0 .70 .18
in the last section, we assume that VL testing is available at 15% of patient visits. The
optimal tripartite rules are developed using the nonparametric approach as described in
Section 3.
Figure 4 shows the estimated optimal rules and associated FNR and FPR, for λ varying
from 0 to 1. The FNR and FPR are computed using 10-fold cross validations, carried out
as follows. We randomly subdivide the data into 10 subsets of about equal size; determine
the FPR and FNR for each subset using the optimal rule developed using the remaining
9 subsets; and then calculate the FPR and FNR as the averages over the 10 pieces (cf.
Hastie et al. 2001).
As shown in Figure 4, when λ increases (i.e., placing higher priority on avoiding false
negative diagnoses), the estimated optimal rule shifts gradually toward triaging the VL
tests to those with CD4 count in the middle and high range. At λ = .8, the estimated
optimal rule calls for testing patients having CD4 count between 300 and 450; in this case,
both FNR and FPR are around .30. At the extreme when λ = 1, the estimated optimal rule
calls for VL tests on those with CD4 > 650, which reduces the FNR to ≈ 0 but increases
FPR to ≈ .80.
The left panel of Figure 4 shows that when λ < .4, the estimated optimal rule is to
obtain VL when 17 < CD4 < 201. That is, when avoidance of false positive diagnosis
is prioritized, the simple rule using VL testing as a confirmative test is optimal and a
reasonable choice.
6.5 Analysis II: Comparing S1- and S2-Based Rules that Minimize the Weighted Risk R3
Next, we compare the diagnostic accuracy of single-maker tripartite rules based on S1 to
multiple-marker rules based on S2 using R3(·) as the risk criterion. We consider three
values of λ = (.25, .50, .75) and three constraints on VL test availability φ = (0, .15, .30).
Nonparametric estimates of the optimal rules, along with FPR, FNR and TMR obtained
from cross-validations, are given in Table 4. Standard errors for all table entries are com-
puted using the bootstrap method with 500 re-samples.
In summary, the optimal rules based on S2 have a slightly better diagnostic perfor-
mance than the optimal rules on S1. However, the magnitude of improvement by incor-
porating more non-VL markers is small, relative to the improvement that can be achieved
by the selective use of VL testing on more patients. In Section 6.7, the diagnostic accura-
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Figure 4: The optimal min-λ rules based on S1 and associated FPR and FNR.
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Table 4: Comparison of the S1- and S2-based tripartite rules. The optimal cut-off points
based on S1 are transformed back to the original scale of CD4 count. The numbers in
parentheses are standard errors.
cut-off points
λ φ lower upper FNR FPR R3 TMR
S1 .25 .00 17 (17) 17 (17) .98 (.02) .00 (.00) .06 (.01) .24 (.02)
.15 17 (9) 201 (18) .72 (.04) .00 (.00) .04 (.00) .18 (.01)
.30 17 (13) 284 (13) .46 (.04) .00 (.00) .03 (.00) .12 (.01)
.50 .00 120 (64) 120 (64) .93 (.12) .03 (.04) .12 (.01) .26 (.02)
.15 90 (16) 216 (39) .63 (.06) .02 (.01) .08 (.01) .17 (.01)
.30 17 (15) 284 (32) .45 (.04) .01 (.01) .05 (.01) .12 (.01)
.75 .00 302 (45) 302 (45) .43 (.06) .26 (.06) .13 (.01) .30 (.04)
.15 216 (51) 317 (50) .40 (.07) .13 (.06) .10 (.01) .20 (.04)
.30 226 (67) 417 (81) .30 (.07) .14 (.06) .08 (.01) .18 (.04)
S2 .25 .00 .64 (.04) .64 (.04) .91 (.04) .01 (.00) .06 (.00) .23 (.01)
.15 .39 (.01) .75 (.04) .62 (.04) .00 (.00) .04 (.00) .16 (.01)
.30 .29 (.01) .71 (.04) .42 (.04) .00 (.00) .03 (.00) .11 (.01)
.50 .00 .53 (.07) .53 (.07) .79 (.08) .04 (.02) .11 (.01) .23 (.01)
.15 .37 (.01) .66 (.06) .60 (.05) .01 (.01) .07 (.01) .16 (.01)
.30 .28 (.01) .67 (.06) .43 (.04) .01 (.01) .05 (.01) .11 (.01)
.75 .00 .26 (.04) .26 (.04) .35 (.08) .30 (.08) .12 (.01) .31 (.04)
.15 .26 (.04) .34 (.05) .32 (.08) .21 (.07) .09 (.01) .24 (.03)
.30 .19 (.03) .34 (.08) .25 (.06) .13 (.05) .07 (.01) .16 (.03)
19
Figure 5: Empirical and semiparametric estimates of the cumulative densities of CD4
counts and log10(CD4).
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cies of the rules based on the two risk scores will be further compared using AUCs.
6.6 Analysis III: Optimal Rules under Exponential Tilt Assumption
In this section, we develop the optimal tripartite rules under the exponential tilt assump-
tion. We consider the following two risk scores, S1 and S
∗
1 = − log10(CD4), for rule de-
velopment. The reason for using S∗1 is that it avoids the issue of having the empirical
adjustment when one cut-off value is beyond the support of the risk score (as we en-
countered in our simulation studies). The risk score S∗1 may also be more suitable for the
exponential tilt model.
We first examine the suitability of the exponential tilt model for S1 and S
∗
1 by plotting
the semiparametric estimates of G0 and G1 against their empirical estimates. The results
are shown in Figure 5, where the semiparametric estimates of G0 and G1 are obtained
using the results in Appendix A.1. Figure 5 suggests that the exponential tilt assumption
is reasonable for both S1 and S
∗
1 although the goodness of fit for S1 is slightly better. (One
also can use Q-Q plots, not shown, to examine the model goodness of fit.)
The estimated optimal rules using TMR as the risk criterion are given in Table 5. The
intervals for triaging VL assays are centered at CD4 = 77 and 109 for the optimal rules
based on S1 and S
∗
1 , respectively. Overall, the diagnostic accuracies of the two sets of
estimated optimal rules are comparable, and their estimated cut-off values differ only
slightly relative to their standard errors. The optimal rules in Table 5 also are comparable
to the optimal rules that are developed nonparametrically (see Table 4 with λ = .50), but
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Table 5: The optimal min-TMR rules under the exponential tilt assumption. Cut-off points
were transformed back to the original scale of CD4 count. The numbers in parentheses
are standard errors calculated using the bootstrap method.
cut-off points
φ lower upper FNR FPR TMR
S1 0 77 (46) 77 (46) .94 (.06) .01 (.02) .24 (.02)
.15 0 (29) 199 (10) 69 (.05) .00 (.01) .17 (.02)
.30 0 (10) 278 (11) .47 (.04) .00 (.00) .11 (.01)
S∗1 0 109 (23) 109 (23) .89 (.05) .03 (.01) .24 (.02)
.15 57 (22) 206 (10) .67 (.04) .01 (.01) .18 (.02)
.30 41 (17) 287 (12) .46 (.04) .01 (.00) .12 (.01)
in general have much smaller standard errors.
6.7 Analysis IV: ROC Analyses for Tripartite Rules
Figure 6 shows nonparametric estimates of ROC curves for tripartite rules based on S1
and S2, when the VL tests are available at φ = 0, 15, 30, 45, and 60% of patient visits. The
ROC curves in the subplot (b) are slightly better than those in the subplot (a), which sug-
gests that improvement in diagnostic capacity can be achieved using the composite score
S2. See also the AUC curves and their difference in the subplots (c) and (d). Consistent
with our findings in Analysis II (Section 6.5), the difference between the two AUC curves,
although statistically significant for φ < .6, is marginal.
Relative to not having VL tests available, the AUCs for tripartite rules based on both
risk scores are substantially improved as VL testing is made available for some of clinical
visits. For example, as shown in the subplot (c), when we increase the VL test availability
from 0 to 20%, the absolute improvement in AUC is about 15%; and increasing availability
to 40% improves AUC by more than 20%. In particular, the relative improvement by mak-
ing VL testing accessible to some HIV patients is more pronounced when the VL testing
availability is low.
7. DISCUSSION
This paper is motivated by recent evidence that the CD4-basedWHOguidelines for moni-
toring HIV treatment in RLS can lead to high treatment failure misclassification rates, and
by the fact that VL tests are becoming available to programs and patients in RLS, typically
on a limited basis. Tomake optimal use of VL tests, we propose a tripartite diagnostic rule
based on a risk score that subdivides patients into a high-risk group (classified as treat-
ment failure), a low-risk group (as viral suppressed), and an intermediate-risk group to
whom the limited VL tests are assigned, where the size of the third group is constrained
by the availability of VL tests. Nonparametric and semiparametric methods are proposed
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Figure 6: ROC curves for diagnostic rules using S1 and S2 (subplots (a) and (b)); the result-
ing AUC curves as functions of φ (subplot (c)); and the difference of the two AUC curves
(S2 “minus” S1, subplot (d)). The point-wise 95% CI of the difference in AUC is calculated
using the bootstrap method with 500 re-samples.
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for determining an optimal rule to minimize a given risk criterion. ROC analysis proce-
dure for characterizing the diagnostic performance of tripartite rules and its associated
asymptotic properties are developed.
Our proposed method is demonstrated by analyzing data from the Miriam Hospital
Immunology Clinic in Providence, RI. We show that with selective and targeted use of
VL tests, the rate of misdiagnosis can be substantially reduced even when VL testing is
available at a small portion of patient visits (e.g., φ = 15%). Our analysis also suggests
that when avoidance of false positive diagnoses is prioritized, using VL testing strictly
to confirm viral failure for those deemed to be at high risk is a reasonable choice. This
finding applies only to patients at the Miriam Hospital Immunology Clinic; its external
validity remains to be tested.
Our methods assume that the functional form of risk score S(X) is known, but may
be relaxed by unknown parameters. When the function form of S(X) is unknown, meth-
ods of machine/statistical learning, such as boosting (Freund et al. 1999), targeted/super
learner (Sinisi et al. 2007; van der Laan 2011), classification tree learning (Breiman et al.
1984), neural networks (Hagan et al. 1996; Sarle 1994), and prediction-based classification
methods (Foulkes and De Gruttola 2002), can be implemented. We refer the readers to
Hastie et al. (2001) and Kotsiantis (2007) for a more comprehensive treatment on the topic.
We assume that there is no measurement error in VL, i.e. that VL test is the gold stan-
dard for determining the amount of circulating virus. In developed countries, repeated
VL tests and HIV genotyping are usually required to confirm treatment failure and ex-
istence of drug resistance once the VL becomes detectable. HIV-infected patients in RLS
however do not have such luxury, and a single VL test result (if done) is probably the
most direct measure of viral failure, and is used for clinical decision making. So although
the assumption is not ideal, it is reasonable in this context because the measured VL is
the best available basis for decision making in RLS. Future work will address the issue of
measurement error in VL and its effect on misclassification rates.
CD4 counts are known to be highly variable due to measurement error, diurnal varia-
tions, and other factors. The measurement error of CD4 count may be part of the reason
for high misclassification rates of the WHO guidelines. The impact of measurement er-
ror in biomarkers on predicting binary outcomes has been studied by Carroll et al. (1984,
2006), Buzas et al. (2003), and Fuller (2009) among others. Generally speaking, large mea-
surement errors of a biomarker are associated with a greater attenuation of its capability
of predicting outcomes. One way to reduce the impact of measurement errors is through
repeated measurements. Given the fact that point-of-care CD4 technologies are being
developed, it may be possible in practice in the future to quantify and reduce the im-
pact of CD4 measurement error by multiple testing at a single visit. On the other hand,
with additional information such as prior history of CD counts, it may also be possible
to evaluate the magnitude of measurement error by constructing appropriate measure-
ment error models (which typically rely on certain subjective assumptions) and apply-
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ing methods such as regression calibration (Carroll and Stefanski 1990; Rosner et al. 1990)
and simulation-extrapolation (Stefanski and Cook 1995). Improving diagnostic accuracy
by reducing the impact of CD4 measurement error is an area worthwhile further investi-
gation.
A final limitation of this paper, as it applies to developing rules for RLS, is that a US
data set is used to demonstrate our proposed methods. Our ongoing work is focused on
developing and calibrating rules based on data from sub-Saharan Africa and other RLS.
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APPENDIX A.
A.1 Semiparametric estimates of G0, G1, and G under the exponential tilt assumption
Suppose that we want to estimate the mixture distribution G using an i.i.d sample of
{(Si,Zi) : i = 1, . . . , n}. In the spirit of nonparametric likelihood estimation, we consider
only the distributions with jumps at {Si}. Thus the (profile) likelihood for G0 can be
written as (see Qin 1999)
L(G0) ∝ ∏
{Zi=0}
g0(Si) ∏
{Zi=1}
exp(β̂∗0 + β̂1Si)g0(Si)
= {
n
∏
i=1
θi} ∏
{Zi=1}
exp(β̂∗0 + β̂1Si),
where β̂∗0 = β̂0 − logit( p̂), β̂0 and β̂1 are the MLEs from the logistic regression (6), and
θi = g0(Si) denotes the mass at the observed Si with ∑i θi = 1. Here we proceed as if we
have n distinct values in {Si}, which does not affect the following results. Applying the
Lagrange multiplier, one can show that the likelihood is maximized at
θ̂i =
1
n
[
1+ ν{exp(β̂∗0 + β̂1Si)− 1}
]−1
,
where ν is the Lagrange multiplier solving
n
∑
i=1
exp(β̂∗0 + β̂1Si)− 1
1+ ν{exp(β̂∗0 + β̂1Si)− 1}
= 0.
We then estimate G0, G1, and G semiparametrically by
G˜0(s) =
n
∑
i=1
θ̂i1{Si < s},
G˜1(s) =
n
∑
i=1
e(β̂
∗
0+β̂1Si)θ̂1{Si < s},
G˜(s) = (1− p̂)G˜0 + p˜G˜1.
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Because the exponential tilt assumption places no constraint on the marginal distribu-
tion G, it can be verified that the semiparametric estimate G˜(s) is equal to the empirical
estimate Ĝ(s).
A.2 Properties of AUCφ for tripartite rules
Property A.2.1: Let S ∼ G1, S′ ∼ G0, and S and S′ be independent. Then,
AUCφ = Pr{S > Hφ(S′)}+ 1
2
Pr{S = Hφ(S′)}, (A.1)
and
AUCφ =
1
2
(
1+ EG1 [G0(S)]− EG0 [G1{Hφ(S′)}]
)
. (A.2)
Proof: We have
AUCφ =
ˆ −∞
∞
{1− G1(Hφ(u))}d(1− G0(u))
=
ˆ ∞
−∞
Pr(S > Hφ(u))dG0(u)
⇒ (A.1),
where 12 Pr(X = Hφ(X
′)) is added for ties and the term vanishes for continuous S. Further,
AUCφ = 1−
ˆ ∞
−∞
G1(Hφ(u))dG0(u)
=
ˆ ∞
−∞
G0(u)dG1(Hφ(u))
⇒ (A.2).

Property A.2.2: If S is stochastically greater than S′, then AUCφ is bounded by
1
2
+ φ− φ
2
2
≤ AUCφ ≤ 1.
The lower bound is achieved when G1 = G0, and the upper bound when φ = 1.
Proof: We prove the results for the case when S is continuous such that there exist l and
u with G(u)− G(l) = φ. Manipulating this constraint slightly, we have 1− G(l) = 1−
G(u) + φ ⇒ 1− {pG1(Hφ(u)) + (1− p)G0(Hφ(u))} = 1− {pG1(u) + (1− p)G0(u)}+ φ.
The condition that S is stochastically greater than S′ implies that
1− G1(Hφ(u)) ≥ 1− {pG1(u) + (1− p)G0(u)}+ φ
≥ 1− G0(u) + φ.
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Therefore,
AUCφ =
ˆ −∞
u=∞
{1− G1(Hφ(u))}d(1− G0(u))
≥
ˆ −∞
u=∞
[{1− G0(u) + φ} ∧ 1]d(1− G0(u))
=
ˆ G−10 (φ)
u=∞
{1− G0(u) + φ}d(1− G0(u)) +
ˆ −∞
u=G−10 (φ)
d(1− G0(u))
=
1
2
+ φ− φ
2
2
.
All equalities hold when G0 = G1. 
A.3 Asymptotic properties of estimated ROC curve and AUC
The nonparametric estimate Ĉφ given by (9) has the following properties:
Property A.3.1: The nonparametric estimate Ĉφ is uniformly consistent.
Proof: Let us write
sup
t
|Ĉφ(t)− Cφ(t)| = sup
t
|Ĝ1 ◦ Ĥφ ◦ Ĝ−10 (t)− G1 ◦ Ĥφ ◦ Ĝ−10 (t)|
+ sup
t
|G1 ◦ Ĥφ ◦ Ĝ−10 (t)− G1 ◦ Hφ ◦ Ĝ−10 (t)|
+ sup
t
|G1 ◦ Hφ ◦ Ĝ−10 (t)− G1 ◦ Hφ ◦ G−10 (t)|.
Then, it can be shown that the first term converges to zero almost surely by the Glivenko-
Cantelli Theorem, and the second and third terms converge to zero almost surely by the
Law of Large Numbers. See Hsieh and Turnbull (1996). 
Property A.3.2: Suppose that the densities g0, g1 and g are continuous and bounded, and∑ Zi/n→
p as n→ ∞. Then, the following approximation holds asymptotically as n→ ∞,
n
1
2 {Ĉφ(v)− Cφ(v)} = 1√
p
B1 ◦ Cφ(v) + g1 ◦ H ◦ G
−1
0 (1− v)
√
1− ρ
g ◦ G−1{G ◦ G−10 (1− v)− φ}
B{G ◦ G−10 (1− v)− φ}
+
1√
1− p
g1 ◦ H ◦ G−10 (1− v)
g0 ◦ G−10 (1− v)
g ◦ G−10 (1− v)
g ◦ G−1{G ◦ G−10 (1− v)− φ}
B2(1− v),
where B1(v) and B2(v) are independent Brownian bridges, B(v) = B1(v)/
√
p+ B2(v)/
√
1− p,
and ρ = {G ◦ G−10 (v)− φ}{1− G ◦ G−10 (v)}/[G ◦ G−10 (v){1− G ◦ G−10 (v) + φ}].
The strategy for proving A.3.2 is similar to Hsieh and Turnbull (1996).
Property A.3.3: The nonparametric estimate ÂUCφ given by (10) has the property that, as n →
∞,
n1/2σ−1/2(ÂUCφ −AUCφ) d−→ N (0, 1), (A.3)
where σ2 = VarG1{G0 ◦ Hφ(S)}p−1 +VarG0{G1 ◦ Hφ(S)}(1− p)−1.
Proof: We prove (A.3) using the properties of U-statistics (Lee 1990). Applying the Ha´jek
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projection principle on (10) (van der Vaart 1998), we express ÂUCφ as
ÂUCφ = AUCφ + A˜n + o(1/n),
where
A˜n =
1
∑i Zi
∑
i
Zi[Ĝ0 ◦ Ĥφ(Si)− EĜ1{Ĝ0 ◦ Ĥφ(Si)}]
+
1
∑i(1− Zi) ∑i
(1− Zi)[Ĝ1 ◦ Ĥφ(Si)− EĜ0{Ĝ1 ◦ Ĥφ(Si)}]
is a U-statistic. Then conditional on ∑i Zi, an ancillary statistic for the AUC, (A.3) is an
immediate result of applying Slutsky’s lemma and the Central Limit theorem. 
33
